CRISPR Therapeutics AG (CRSP)
50.76
+4.37
(+9.42%)
USD |
NASDAQ |
Nov 01, 16:00
50.80
+0.04
(+0.08%)
After-Hours: 20:00
CRISPR Therapeutics Shareholders Equity (Quarterly): 1.981B for June 30, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 1.981B |
| March 31, 2024 | 2.084B |
| December 31, 2023 | 1.883B |
| September 30, 2023 | 1.728B |
| June 30, 2023 | 1.816B |
| March 31, 2023 | 1.855B |
| December 31, 2022 | 1.875B |
| September 30, 2022 | 1.954B |
| June 30, 2022 | 2.091B |
| March 31, 2022 | 2.245B |
| December 31, 2021 | 2.399B |
| September 30, 2021 | 2.513B |
| June 30, 2021 | 2.604B |
| March 31, 2021 | 1.805B |
| December 31, 2020 | 1.664B |
| September 30, 2020 | 1.343B |
| June 30, 2020 | 910.67M |
| Date | Value |
|---|---|
| March 31, 2020 | 886.10M |
| December 31, 2019 | 939.42M |
| September 30, 2019 | 591.88M |
| June 30, 2019 | 367.68M |
| March 31, 2019 | 379.81M |
| December 31, 2018 | 392.20M |
| September 30, 2018 | 417.31M |
| June 30, 2018 | 265.15M |
| March 31, 2018 | 290.34M |
| December 31, 2017 | 187.83M |
| September 30, 2017 | 178.96M |
| June 30, 2017 | 197.80M |
| March 31, 2017 | 215.18M |
| December 31, 2016 | 232.85M |
| September 30, 2016 | -62.48M |
| June 30, 2016 | 135.34M |
| December 31, 2015 | -29.10M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
886.10M
Minimum
Mar 2020
2.604B
Maximum
Jun 2021
1.820B
Average
1.875B
Median
Dec 2022
Shareholders Equity (Quarterly) Benchmarks
| Vertex Pharmaceuticals Inc | 14.77B |
| AC Immune SA | 137.30M |
| Addex Therapeutics Ltd | 14.07M |
| NLS Pharmaceutics Ltd | -9.268M |
| Molecular Partners AG | 173.06M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 2.340B |
| Total Liabilities (Quarterly) | 358.90M |